Kornimate/medical-research-clean huggingface dataset:
sympatholytic effect of thoracic esp

Conditions: Pain, Chronic

Summary: the primary endpoint of this study was to identify if erector spinae plane bloock (espb) demonstrates any sympatholytic effect. the secondary endpoint of this study was to compare the changes of pi value between responders and non-responders.

the erector spinae plane block (espb) is a less invasive, safer, and technically easy alternative procedure to conventional neuraxial anesthetic techniques. in contrast to common neuraxial techniques such as paravertebral and epidural injections, the espb targets an interfascial plane which is far from the spinal cord, root, and pleura. first applied to thoracic neuropathic pain, currently espb is being applied to postoperative pain control and includes variable clinical situations. in the abdomen and thoracic wall, thoracic espb can be applied for pain control after cardiac surgery, video-assisted thoracic surgery, laparoscopic cholecystectomy, and thoracotomy. recently, favorable postoperative pain control after lumbar spinal or lower limb surgeries has been reported with lumbar espb. in addition, espb has also been used for chronic pain conditions in the upper and lower extremities. the perfusion index (pi) is a numerical value for the ratio between pulsatile and non-pulsatile blood flow measured by a special pulse oximeter. although the special probe for pi measurement is relatively more expensive compared with ordinary pulse oximetery probes, its benefit as a marker of peripheral perfusion and as an idex for sympathetic stimulation have increased its use progressively. espb can achieve analgesic effect by blocking the ventral and doramal ramus and possibly by diffusion into paravertebral space. in constrast to lumar region, thoracic paravertebral space is very close to the sympathetic chain. therefore, sympatholytic effect might be achieved by thoracic espb. no previous study has demonstrated the sympatholytic effect of espb.

Eligibility criteria:
inclusion criteria: * complex regional pain syndrome * post-thoracotomy pain syndrome * cervical foraminal stenosis * cervical disc herniation * herpes zoster exclusion criteria: * pregnacy * coagulation abormality * previous spine surgery * allergy to local anesthetics
nicotinic receptors and schizophrenia

Conditions: Schizophrenia

Summary: the study determines if a new preparation of a drug designed to treat schizophrenia is more slowly released into the body.

3-2,4 dimethoxybenzylidene will be compounded with a methyallose compound in doses of 150 and 300 mg. the capsules will be administered singly and eventually bid to determine if sustained blood levels comparable to steady state blood levels seen in previous studies can be determined. safety and eeg effects will be measured.

Eligibility criteria:
inclusion criteria: * healthy volunteers: males and females who are incapable of pregnancy exclusion criteria: * medical illnesses requiring acute treatment * history of seizures * substance abuse including nicotine

Keywords: receptors nicotinic
characterizing matrix metalloproteinase-12 (mmp12) in sputum

Conditions: Emphysema

Summary: the hypothesis is that in patients with emphysema, a high mmp12 sputum and/or blood level correlates with airspace enlargement and with increased sputum th2 immune biomarkers.

since mmp-12 apparently has a preponderant role in the genesis of emphysema and probably in airspace enlargement, its inhibition may result in an interesting targeting point in view to find specific therapies in obstructive diseases. there is abundant evidence in animal models that shows how mmp-12 blockade inhibits the development of emphysema and airway remodeling. unfortunately, the results have not been conclusive in human models. in the last years, pulmonary imaging biomarkers that measure airspace enlargement have been developed. in particular, the apparent diffusion coefficient (adc), quantified by inhaled hyperpolarized gas mri, reflects alveolar airspace size. adc provides information consistent with histopathological findings that may be used to estimate lung disease progression and treatment response.

Eligibility criteria:
inclusion criteria (copd): * ≥40 years of age * current or ex-smokers with a \>10 pack year smoking history * have a post-bronchodilator forced expired volume in 1 second (fev1)/forced expired vital capacity (fvc) ratio of \<70% and a post-bronchodilator fev1 value from ≥30% predicted (gold 1, 2 and 3), (global initiative for obstructive lung disease) * have a radiologist confirmed pulmonary emphysema diagnosis based on ct inclusion criteria for normal controls: * no clinically significant medical condition or a history of asthma, copd, cystic fibrosis, or other significant respiratory disorder including significant occupational or environmental exposures with ongoing respiratory symptoms. * no current or past smoking history * have a post-bronchodilator fev1/fvc ratio of \>70% exclusion criteria: any potential subject who meets any of the following criteria will be excluded from participating in the study: * patients with other non-copd airway diseases * patients with very severe copd (fev1\<30% predicted) * patients with an intercurrent exacerbation * patients with life expectancy less than 3 months * pregnant or breastfeeding * undergoing immunomodulatory or biologic treatment * use of systemic steroids in the last month * hospitalization in the last 12 months due to exacerbation * known cardiovascular comorbidity under treatment or with hospitalizations of this cause in the last year * that they cannot perform spirometry * active malignancy * realization of lung surgery during the study period * history of alcohol and drug abuse that prevents compliance with follow-up * history of bronchial thermoplasty * participating in another study concomitantly * mri related: patients who have implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, artificial limb, metallic fragments of foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants).
impact of prior sglt2 inhibitors use on the development and progression of sepsis-associated acute kidney injury

Conditions: Sepsis; Septic Shock; Acute Kidney Injury

Summary: the primary objective of this study is to investigate whether using sglt2i may be associated with decreased incidence of sepsis-induced aki or not.

the primary objective of this study is to investigate whether using sglt2i may be associated with decreased incidence of sepsis-induced aki or not.

Eligibility criteria:
inclusion criteria: * all adult (≥ 18 year) patients who were admitted to icu with sepsis syndromes (sepsis or septic shock), according to sepsis-3 definition. exclusion criteria: * missing data * renal transplant or tumor * solitary kidney * established ckd * obstructive uropathy * renal artery stenosis * pregnancy

Keywords: sepsis acute kidney injury sepsis-associated acute kidney injury sglt2i
work of breathing description in neonates with congenital diaphragmatic hernia in nava and in conventional ventilation.

Conditions: Hernia, DIaphragmatic, Congenital

Summary: congenital diaphragmatic hernia (cdh) is a congenital malformation associated with significant mortality and respiratory morbidity, particularly related to prolonged mechanical ventilation. nava (neurally adjusted ventilatory assist) is a recent technique that uses the recognition of the electrical activity of the patient's diaphragm (edi) and delivers a synchronized proportional assisted ventilation. this technique has already been used in the newborn, especially premature and has shown many benefits. only one study in the literature shows its feasibility in newborns with cdh. this technique seems interesting in the context of cdh because it would limit baro-trauma and improve synchronization. before demonstrating the clinical benefits, it seems important to describe the effects on the respiratory physiology, in particular on work of breathing which can be estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer. our study is an innovative physiologic pilot study with the objective to describe work of breathing in neonates with cdh in post-surgical period in nava ventilation and in conventional ventilation using an esophageal transducer. it will provide the clinician with a physiological justification for the use of nava to rapidly improve the respiratory muscular dynamics of these patients. this study is a prerequisite for the realization of studies demonstrating the clinical benefit of nava ventilation on reduction of duration of ventilation and more generally on morbidity and mortality in the population of neonate with cdh.


Eligibility criteria:
inclusion criteria: * neonate admitted to neonatal intensive care beyond 34 weeks of amenorrhea * with a diagnosis of congenital diaphragmatic hernia having undergone a repair surgery. * necessary invasive ventilatory support by conventional ventilation * informed and signed consent of parents (and / or holders of parental authority) exclusion criteria: * refusal of parents (and / or holders of parental authority) to participate in the study * contra-indication to the use of an oro or naso-gastric tube (oesophageal surgery) * child at risk of poor tolerance to the placement of the oesophageal pressure transducer (history of discomfort when placing a tube, weight \<1500g) * central or neuromuscular neurological pathology which may affect respiratory control

Keywords: hernia, diaphragmatic, congenital respiration, artificial physiologic pilot study nava neurally adjusted ventilatory assist esophageal transducer work of breathing
the model for end-stage liver disease sodium (meld-na) score in non-cirrhotic patients with gastric cancer

Conditions: Gastric Cancer; Complication,Postoperative; Complications; Gastrointestinal, Postoperative; Morality

Summary: gastric cancer is the fifth most common cancer worldwide. gastrectomy with lymphadenectomy is still the most effective treatment modality, depending on the stage and location. despite many radiological, surgical and anesthetic innovations, serious complications such as anastomotic leakage, intra-abdominal abscesses, wound complications are seen secondary to gastrectomy. many clinical studies have been conducted to prevent and predict these complications. the model for end-stage liver disease (meld) score, in which bilirubin, international normalized ratio (inr) and serum creatinine values were used to determine surgical risks in patients scheduled for liver transplantation. latter developed by adding serum sodium (na) to the formula. the meld-na score is used to predict postoperative complications in non-cirrhotic patients because of its simple and easy calculation.moreover, the meld-na score was later used to predict complications for surgical procedures other than liver surgery such as colorectal surgery. in this study, we aimed to investigate the importance of the meld-na score in predicting the perioperative and postoperative outcomes in patients with gastric cancer.


Eligibility criteria:
inclusion criteria: * patients undergoing gastrectomy due to gastric cancer exclusion criteria: * patients with pulmonary, hepatic and renal disfunctions, * patients with diagnosed with a different cancer in the last 5 years and * pregnant patients
response of continuous recombinant antithrombin infusion in postcardiotomy ecmo patients

Conditions: Antithrombin Deficiency Type 2

Summary: the objective of this study will be to prospectively evaluate the response of a continuous infusion of recombinant human antithrombin concentrate (rhat) (atryn®) to achieve and maintain the at activity within a specified range in adult patients that require extracorporeal membrane oxygenation (ecmo) following cardiopulmonary bypass (cpb) and cardiac surgery.


Eligibility criteria:
inclusion criteria: * completed cardiac surgery with cardiopulmonary bypass and subsequently placed on venoarterial (va) extracorporeal membrane oxygenation (ecmo) support at any point during the ongoing hospitalization * serum antithrombin \< 60%. exclusion criteria: * heart transplantation during ongoing hospitalization * excessive bleeding (300 ml/hr of chest tube drainage for 2 consecutive hours) * weight \< 40 kg * allergy to goat products * anticoagulation with a direct thrombin inhibitor * religious exception to blood products * hypothermia (\< 34°c)
focused assessment with sonography in trauma

Conditions: Trauma; Ultrasonography

Summary: the study evaluates the knowledge and attitude about focused assessment with sonography in trauma examination among medical students and medical staff in poland.


Eligibility criteria:
inclusion criteria: * give voluntary consent to participate in the study exclusion criteria: * not meet the above criteria

Keywords: attitudes knowledge examination
partial double-blind, placebo-controlled study to assess the effect of anastrozole on the endometrium in healthy volunteers

Conditions: Menstruation Disorders

Summary: aromatase inhibitors have been approved for use in postmenopausal women to treat and prevent breast cancer. they act by blocking the action of the enzyme, aromatase, that is necessary for the production of estradiol. this class of drugs, aromatase inhibitors, are very effective in reducing estradiol levels in postmenopausal women and in treating estrogen receptor positive breast cancers. this study is examining the effect of a specific inhibitor, anastrozole, on endometrial thickness in premenopausal women. the endometrium is sensitive to estradiol and also has local aromatase which, if inhibited, may result in reduced endometrial thickness. the main hypothesis is that anastrozole can be administered at any time during the menstrual cycle and reduce endometrial thickness compared to placebo.


Eligibility criteria:
inclusion criteria: * between the ages of 25 and 45 and pre-menopausal; * non-lactating and not pregnant * able to follow the schedule of procedures * able to freely provide informed consent * have clinically acceptable physical examination and safety laboratory studies exclusion criteria: * current use of any form of systemic contraceptive * have self-reported irregular menstrual cycles * intercurrent illness(es) detected on the screening physical * unwilling or unable to use barrier methods of contraception * have evidence of endometrial polyps or myomata on tvu/sis that would interfere with endometrial thickness measurement * detection of ovarian cyst(s) during adnexal examination on screening tvu/sis measuring greater than 5 cm * have history of, or current cancer, on any form exclusive of basal cell carcinoma * bmi \>= 35 * history of alcohol or drug abuse in the past 5 years * unwilling or unable to undergo study procedures within the necessary time frames * history or current liver abnormalities as defined by alt or ast \> 2x uln * treated or untreated diabetes defined as fasting blood sugar \>= 126 mg/dl * untreated hypertension * impaired renal function by estimated creatinine clearance \< 80ml/min * have estradiol levels \ 40 miu/ml or * have a history of adverse reaction any aromatase inhibitor
propose quality - preotact in postmenopausal osteoporosis - quality of life study (fp-004-de)

Conditions: Postmenopause; Osteoporosis

Summary: the objectives of the study are * to describe the quality of life at the beginning of the preotact® treatment and at the end of the observational period (qualeffo-41 questionnaire) * pain assessment at the beginning of the preotact® treatment and at the end of the observational period (vas score) * to describe bone mineral density at the beginning of the preotact® treatment and at the end of the observational period (t-score) * to describe incidence of bone fractures caused by osteoporosis as well as of other pathological findings of the skeleton after the beginning of the preotact® treatment * to describe serum level of calcium and the bone resorption marker desoxypyridinoline (dpd) and n- respectively c-terminal crosslink-telopeptide (ctx and ntx) at the beginning of the preotact® treatment and at the end of the observational period (only in subgroup of patients, where the physician sees a need to measure these parameters) * to document all adverse drug reactions after the beginning of the preotact® treatment * the analysis of subgroups with different risk for bone fractures caused by osteoporosis at the beginning of the preotact® treatment * to assess the manageability and functioning of the pen system for injection of preotact® (self administered questionnaire)


Eligibility criteria:
inclusion criteria: * inclusion requires that preotact® is prescribed in accordance with the spc and that the stated contraindications are strictly considered. * caution should be taken by the treating physician concerning any precautions, warnings and potential drug interactions stated in the spc. * no further inclusion or exclusion parameters are defined. the decision for the individual application of preotact® will be strictly made by the physicians.

Keywords: osteoporosis postmenopausal women severe postmenopausal osteoporosis
efficacy and safety study of gsk679586 in patients with severe asthma

Conditions: Asthma

Summary: treatment, randomised, double blind, parallel assignment, safety/efficacy study

a multi-centre, multi-country, randomized, double-blind (subject, investigator), placebo-controlled, repeat-dose study to evaluate the efficacy and safety of intravenous gsk679586 in patients with severe asthma

Eligibility criteria:
inclusion criteria: * history of asthma for ≥ 6 months * taking inhaled corticosteroids * non-smoking * baseline (pre-bronchodilator) fev1 35-80% predicted at screening. * reversible airways disease as indicated by an increase of fev1 ≥12% from baseline after nebulised salbutamol or albuterol. * symptomatic according to the acq-7 exclusion criteria: * unstable severe asthma * recent respiratory illness * presence of other respiratory disease or chronic pulmonary condition other than asthma * treatment with omalizumab within 4 months of study * recent gastrointestinal or respiratory parasitic infestation * history of severe allergy to food or drugs other protocol-defined inclusion/exclusion criteria may apply

Keywords: asthma asthma control questionnaire
a cohort of patients with phenotyped diffuse interstitial lung disease with longitudinal follow-up

Conditions: Interstitial Lung Disease

Summary: the purpose of the study is to conduct a descriptive analysis of the population of patients with an interstitial lung disease received in the pulmonary department of university hospital of nice (france). analysis and documentation of clinical forms of the disease, therapeutics used and evolutions.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * diagnosis of interstitial lung disease according to the multidisciplinary monthly meeting for interstitial lung disease occuring at university hospital of nice, france exclusion criteria: * patient-led opposition to data collection
new interactive sensor-home-based hand training to improve dexterity

Conditions: Stroke; Multiple Sclerosis; Parkinson Disease

Summary: primary objective of this study is to explore the impact of a 3-week upper limb hand function training in patients with pd, ms or stroke. the benefits on hand function of this training program will be evaluated. the hypothesize is that the 3-week upper limb hand function training improves finger dexterity.

patients with parkinson's disease (pd), multiple sclerosis (ms) or stroke often suffer from significantly decreased coordination and have difficulties with precise hand/finger movements during the performance of both basic activities of daily living (adl), such as dressing, grooming as well as higher adl, such as cooking, shopping and regular medication intake. the investigators explore the effects of a new, interactive, sensor-home-based upper limb hand training on upper limb related adl in patients with pd, ms or stroke.

Eligibility criteria:
inclusion criteria: * patients with confirmed pd, according to uk brain bank criteria (hughes et al., 1992) or * ms patients with relapsing-remitting ms (rrms), secondary-progressive ms (spms) or primary progressive ms (ppms) according to the revised mcdonald's criteria or * subacute stroke * written and signed informed consent * self-reported hand function problems or * healthy subject * written and signed informed consent * no self-reported hand function problems exclusion criteria: * moca \<21/30 * psychiatric disease * participation on other interventional trials * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.

Keywords: dexterity training
insulin resistance in multiple system atrophy

Conditions: Multiple System Atrophy

Summary: multiple system atrophy (msa) is a rare and fatal neurodegenerative disorder. the pathologic hallmark is the accumulation of aggregated alpha-synuclein in oligodendrocytes forming glial cytoplasmic inclusions. some symptomatic treatments are available while disease-modification remains an unmet treatment need. post-mortem findings suggest insulin resistance, i.e. reduced insulin signaling, in the brains of msa patients. the aim of this study is to complete the target validation of insulin resistance for future treatment trials.

multiple system atrophy (msa) patients have a poor prognosis with a median survival ranging between 6 and 10 years. msa belongs to the synucleinopathies, which are characterized by the abnormal accumulation of alpha-synuclein. we have recently shown brain insulin resistance (i.e. reduced insulin signaling) in post-mortem brain tissue of msa patients and transgenic msa mice, as illustrated by increased protein levels of insulin receptor substrate-1 phosphorylated at serine 312 (irs-1ps312). additionally, exendin-4, an approved anti-diabetic drug targeting glucagon-like peptide-1 (glp-1) receptors, was capable of decreasing brain levels of irs-1ps312 and preserving dopamine neurons in transgenic msa mice. we further observed an inverse correlation between plasma neural-derived exosomal irs-1ps312 levels and survival of dopamine neurons in transgenic msa mice. the aim of this study is to further characterize peripheral and central insulin resistance in msa patients, thereby validating this target for future treatment trials. for this purpose, fasting blood glucose and insulin levels will be determined in samples of msa patients and healthy controls for a homeostatic model assessment of insulin resistance (homa). additionally, irs-1ps312 will be measured in neural-derived plasma exosomes of msa patients and healthy controls.

Eligibility criteria:
inclusion criteria: patients : * patients suffering from "possible" or "probable" msa according to clinical consensus criteria (gilman et al., 2008). * age \> 30 * written informed consent * patient covered by the national health system controls: * patients not suffering from a neurologic disorder * age \> 30 * written informed consent * patient covered by the national health system exclusion criteria: for patients and controls: * presence of a diabetes * treatment with corticosteroids, estrogen, atypical antipsychotics, and anti-retroviral agents * patient under tutelage * patient unable to give consent * any other neurologic disorder * pregnancy and breastfeeding * moca ≤21 * contraindication to perform an mri

Keywords: multiple system atrophy neurodegenerative disease alpha synuclein insulin resistance